摘要
目的探讨唑来膦酸(密固达)治疗女性绝经后及老年骨质疏松症的临床疗效。方法选择120例女性绝经后及老年骨质疏松症的患者随机分为对照组及实验组,实验组应用唑来膦酸(密固达)5 mg 1年1次静滴,同时口服活性维生素D和钙剂,对照组给予平衡盐溶液1年1次,同时口服活性维生素D和钙剂1年。分别于治疗前和治疗后6个月、12个月进行骨密度测量。结果治疗后6个月骨密度稍增加(P>0.05),治疗12个月后骨密度显著升高,与对照组有显著性差异(P<0.01)。结论使用唑来膦酸预防和治疗骨质疏松,能在一定程度上抑制骨量丢失,增加骨密度,改善骨质疏松程度,降低骨折风险,提高老年骨质疏松患者的生活质量。
Objective To study the efficacy of zoledronic acid on postmenopausal and senile osteoporosis. Methods One hundred and twenty patients with postmenopausal and senile osteoporosis were randomly divided into control group and experimental group. Patients in the experimental group were administered with 5mg zoledronic acid intravenously once a year, and oral active vitamin D and calcium. Patients in the control group received balanced salt solution once a year, and oral active vitamin D and calcium. Bone mineral density （BMD） was measured before and 6- and 12-month after the treatment. Results BMD increased slightly after a 6-month treatment （ P 〉 0.05 ）. BMD increased significantly in the experimental group after a 12-month treatment. The difference was significant when compared with that in the control group （P 〈 0.01 ）. Conclusion The use of zoledronic acid can partially inhibit bone loss, increase BMD, ameliorate osteoporosis, reduce fracture risk, and improve the quality of life in senile patients.
出处
《中国骨质疏松杂志》
CAS
CSCD
2011年第10期915-916,902,共3页
Chinese Journal of Osteoporosis
关键词
唑来膦酸
骨质疏松
骨密度
Zoledronic acid
Osteoporosis
Bone mineral density
